Organon & (OGN) Stock Price

Organon & Price

NYSE·CLOSED
13.53USD-0.03 (-0.18 %)
Market closed

Revenue at Organon & has contracted by 6.3% per year over the past 8 years to 6.22 B USD. Earnings per share have declined at 38.0% per year over the last 6 years. Organon &'s net margin stands at 3.0%, down from 21.4% several years earlier. Organon & currently offers a dividend yield of about 2.51%. The payout ratio is around 47% of earnings. Analysts set a median price target of 9.18 USD, implying 32.2% below the current price. Of 16 analysts, 1 rate the stock a buy — an overall Sell consensus. The stock trades about 137% above its 52-week low.

Organon & stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Organon & over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Organon & stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Organon &'s price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Organon & Stock Price History
DateOrganon & Price
7/27/202613.53 USD
7/23/202613.56 USD
7/22/202613.52 USD
7/21/202613.51 USD
7/20/202613.49 USD
7/17/202613.52 USD
7/16/202613.49 USD
7/15/202613.49 USD
7/14/202613.50 USD
7/13/202613.51 USD
7/10/202613.52 USD
7/9/202613.49 USD
7/8/202613.49 USD
7/7/202613.51 USD
7/6/202613.56 USD
7/2/202613.55 USD
7/1/202613.53 USD
6/30/202613.54 USD
6/29/202613.52 USD
6/26/202613.50 USD
6/25/202613.47 USD
6/24/202613.48 USD
6/23/202613.45 USD
6/22/202613.41 USD
6/18/202613.43 USD
6/17/202613.43 USD
6/16/202613.45 USD
6/15/202613.44 USD
6/12/202613.45 USD
6/11/202613.44 USD
6/10/202613.40 USD
6/9/202613.40 USD
6/8/202613.39 USD
6/5/202613.39 USD
6/4/202613.40 USD
6/3/202613.40 USD
6/2/202613.36 USD
6/1/202613.36 USD
5/29/202613.38 USD
5/28/202613.36 USD
5/27/202613.40 USD
5/26/202613.43 USD
5/22/202613.44 USD
5/21/202613.44 USD
5/20/202613.45 USD
5/19/202613.42 USD
5/18/202613.42 USD
5/15/202613.40 USD
5/14/202613.36 USD
5/13/202613.34 USD
5/12/202613.31 USD
5/11/202613.33 USD
5/8/202613.35 USD
5/7/202613.32 USD
5/6/202613.41 USD
5/5/202613.35 USD
5/4/202613.26 USD
5/1/202613.29 USD
4/30/202613.25 USD
4/29/202613.34 USD
4/28/202613.32 USD
4/27/202613.16 USD
4/24/202611.26 USD
4/23/20268.60 USD
4/22/20269.14 USD
4/21/20268.84 USD
4/20/20269.26 USD
4/17/20269.76 USD
4/16/20269.33 USD
4/15/20269.21 USD
4/14/20268.70 USD
4/13/20268.54 USD
4/10/20268.83 USD
4/9/20266.91 USD
4/8/20265.86 USD
4/7/20266.12 USD
4/6/20266.05 USD
4/2/20266.36 USD
4/1/20266.14 USD
3/31/20265.99 USD
3/30/20265.70 USD
3/27/20265.84 USD
3/26/20266.05 USD
3/25/20266.10 USD
3/24/20266.11 USD
3/23/20266.09 USD
3/20/20266.03 USD
3/19/20266.27 USD
3/18/20266.23 USD
3/17/20266.39 USD
3/16/20266.34 USD
3/13/20266.35 USD
3/12/20266.33 USD
3/11/20266.40 USD
3/10/20266.48 USD
3/9/20266.53 USD
3/6/20266.56 USD
3/5/20266.71 USD
3/4/20266.87 USD
3/3/20266.90 USD
3/2/20267.19 USD
2/27/20267.29 USD
2/26/20267.23 USD
2/25/20267.51 USD
2/24/20268.14 USD
2/23/20267.92 USD
2/20/20268.10 USD
2/19/20267.52 USD
2/18/20267.46 USD
2/17/20267.28 USD
2/13/20267.39 USD
2/12/20267.06 USD
2/11/20267.69 USD
2/10/20267.81 USD
2/9/20267.91 USD
2/6/20268.21 USD
2/5/20268.10 USD
2/4/20268.29 USD
2/3/20268.00 USD
2/2/20268.20 USD
1/30/20268.54 USD
1/29/20268.60 USD
1/28/20268.89 USD
1/27/20269.00 USD
1/26/20269.10 USD
1/23/20269.76 USD
1/22/20269.74 USD
1/21/20269.59 USD
1/20/20269.46 USD
1/16/20268.76 USD
1/15/20268.70 USD
1/14/20268.61 USD
1/13/20268.43 USD
1/12/20268.12 USD
1/9/20268.05 USD
1/8/20268.13 USD
1/7/20268.19 USD
1/6/20268.07 USD
1/5/20267.44 USD
1/2/20267.24 USD
12/31/20257.17 USD
12/30/20257.13 USD
12/29/20257.11 USD
12/26/20257.18 USD
12/24/20257.09 USD
12/23/20257.09 USD
12/22/20256.98 USD
12/19/20256.83 USD
12/18/20256.84 USD
12/17/20256.99 USD
12/16/20256.97 USD
12/15/20257.02 USD
12/12/20257.17 USD
12/11/20257.36 USD
12/10/20257.18 USD
12/9/20256.95 USD
12/8/20257.29 USD
12/5/20257.14 USD
12/4/20257.14 USD
12/3/20257.27 USD
12/2/20257.49 USD
12/1/20257.60 USD
11/28/20257.71 USD
11/26/20257.74 USD
11/25/20257.51 USD
11/24/20257.06 USD
11/21/20257.20 USD
11/20/20257.13 USD
11/19/20257.45 USD
11/18/20257.71 USD
11/17/20257.65 USD
11/14/20257.53 USD
11/13/20257.62 USD
11/12/20257.71 USD
11/11/20257.52 USD
11/10/20257.71 USD
11/7/20256.78 USD
11/6/20256.71 USD
11/5/20256.38 USD
11/4/20256.52 USD
11/3/20256.71 USD
10/31/20256.75 USD
10/30/20256.57 USD
10/29/20256.34 USD
10/28/20256.66 USD
10/27/20257.06 USD
10/24/20259.16 USD
10/23/20259.05 USD
10/22/20258.94 USD
10/21/20259.02 USD
10/20/20259.24 USD
10/17/20259.28 USD
10/16/20259.38 USD
10/15/20259.55 USD
10/14/20259.56 USD
10/13/20259.60 USD
10/10/20259.60 USD
10/9/20259.92 USD
10/8/202510.24 USD
10/7/202510.60 USD
10/6/202510.84 USD
10/3/202511.01 USD
10/2/202510.94 USD
10/1/202510.99 USD
9/30/202510.68 USD
9/29/202510.35 USD
9/26/202510.21 USD
9/25/202510.12 USD
9/24/202510.41 USD
9/23/202510.54 USD
9/22/202510.57 USD
9/19/202510.45 USD
9/18/202510.85 USD
9/17/202510.45 USD
9/16/202510.36 USD
9/15/202510.40 USD
9/12/202510.65 USD
9/11/202510.66 USD
9/10/202510.26 USD
9/9/202510.37 USD
9/8/202510.47 USD
9/5/202510.38 USD
9/4/20259.68 USD
9/3/20259.83 USD
9/2/20259.42 USD
8/29/20259.42 USD
8/28/20259.18 USD
8/27/20259.20 USD
8/26/20259.07 USD
8/25/20259.06 USD
8/22/20259.43 USD
8/21/20259.28 USD
8/20/20259.37 USD
8/19/20259.26 USD
8/18/20259.28 USD
8/15/20259.44 USD
8/14/20259.39 USD
8/13/20259.36 USD
8/12/20259.05 USD
8/11/20259.01 USD
8/8/20259.22 USD
8/7/20259.11 USD
8/6/20258.72 USD
8/5/20258.40 USD
8/4/20259.67 USD
8/1/20259.75 USD
7/31/20259.70 USD
Access this data via the Eulerpool API
Get Free API Key

Organon & Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
6.26 B USD
1.20 B USD
1.02 B USD
Jan 1, 2024
6.40 B USD
1.33 B USD
864.00 M USD
Jan 1, 2025
6.22 B USD
929.00 M USD
187.00 M USD
Jan 1, 2026 (e)
6.13 B USD
1.33 B USD
880.94 M USD
Jan 1, 2027 (e)
6.24 B USD
1.35 B USD
936.36 M USD
Jan 1, 2028 (e)
6.28 B USD
1.36 B USD
985.52 M USD
Jan 1, 2029 (e)
6.46 B USD
1.40 B USD
987.92 M USD
Jan 1, 2030 (e)
6.51 B USD
1.41 B USD
1.01 B USD

Organon & Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 31, 2026, 11:55 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
10.509.787.786.536.306.176.266.406.226.136.246.286.466.51
–-6.89-20.46-16.01-3.49-2.061.442.24-2.92-1.461.810.642.930.70
56.3052.0070.7667.5662.2162.8459.8458.0254.0954.0954.0954.0954.0954.09
5.915.085.504.413.923.883.753.723.363.313.373.393.493.52
3.272.713.852.851.921.711.201.330.931.331.351.361.401.41
31.1627.6849.4743.5930.3827.6219.1620.7214.9521.6321.6321.6421.6321.63
1.802.153.222.161.350.921.020.860.190.880.940.990.991.01
–19.5449.47-32.88-37.45-32.1211.56-15.54-78.36370.596.365.240.202.63
––––1.121.121.121.120.340.080.080.08––
––––––––-69.64-76.47––––
260.17260.17254.00253.13254.55255.39256.59259.88260.17260.17260.17260.17260.17260.17
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Organon & generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Organon & retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Organon &'s gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Organon & has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Organon &'s historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Organon & stock margins

The Organon & margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Organon &. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Organon &.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
62.21 %
30.38 %
21.43 %
Jan 1, 2022
62.84 %
27.62 %
14.85 %
Jan 1, 2023
59.84 %
19.16 %
16.33 %
Jan 1, 2024
58.02 %
20.72 %
13.49 %
Jan 1, 2025
54.09 %
14.95 %
3.01 %
Jan 1, 2026 (e)
54.09 %
21.64 %
14.38 %
Jan 1, 2027 (e)
54.09 %
21.64 %
15.01 %
Jan 1, 2028 (e)
54.09 %
21.64 %
15.70 %

Organon & Stock Revenue, EBIT, Earnings per Share

The Organon & earnings per share therefore indicates how much revenue Organon & has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
24.77 USD
7.52 USD
5.31 USD
Jan 1, 2022
24.17 USD
6.68 USD
3.59 USD
Jan 1, 2023
24.41 USD
4.68 USD
3.99 USD
Jan 1, 2024
24.64 USD
5.11 USD
3.32 USD
Jan 1, 2025
23.89 USD
3.57 USD
0.72 USD
Jan 1, 2026 (e)
23.56 USD
5.09 USD
3.39 USD
Jan 1, 2027 (e)
23.99 USD
5.19 USD
3.60 USD
Jan 1, 2028 (e)
24.14 USD
5.22 USD
3.79 USD

Organon & business model & stock analysis

Organon & Segments

Organon & Revenue by Segment (1/5)

  • 3 Years

  • Max

Nexplanon/Implanon NXT
Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Other Womens Health
Hadlima
Dulera
Fosamax
Other Women's Health
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Propecia
Ganirelix Acetate Injection
Proscar
Diprosone
Other Respiratory
Brenzys
Jada
Rosuzet
Sinemet
Cerazette
Remeron
Zocor
Asmanex
Other Biosimilars
Aybintio
Details
Date
Nexplanon/Implanon NXT
Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Other Womens Health
Hadlima
Dulera
Fosamax
Other Women's Health
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Propecia
Ganirelix Acetate Injection
Proscar
Diprosone
Other Respiratory
Brenzys
Jada
Rosuzet
Sinemet
Cerazette
Remeron
Zocor
Asmanex
Other Biosimilars
Aybintio
Jan 1, 2021
0.00 USD
458.00 M USD
413.00 M USD
378.00 M USD
223.00 M USD
357.00 M USD
199.00 M USD
186.00 M USD
206.00 M USD
244.00 M USD
237.00 M USD
234.00 M USD
0.00 USD
190.00 M USD
0.00 USD
0.00 USD
191.00 M USD
126.00 M USD
126.00 M USD
125.00 M USD
111.00 M USD
0.00 USD
164.00 M USD
136.00 M USD
111.00 M USD
117.00 M USD
87.00 M USD
26.00 M USD
63.00 M USD
0.00 USD
68.00 M USD
71.00 M USD
70.00 M USD
66.00 M USD
65.00 M USD
63.00 M USD
49.00 M USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
830.00 M USD
519.00 M USD
404.00 M USD
306.00 M USD
319.00 M USD
281.00 M USD
275.00 M USD
278.00 M USD
253.00 M USD
257.00 M USD
262.00 M USD
0.00 USD
44.00 M USD
194.00 M USD
159.00 M USD
171.00 M USD
152.00 M USD
155.00 M USD
155.00 M USD
91.00 M USD
136.00 M USD
134.00 M USD
129.00 M USD
125.00 M USD
110.00 M USD
97.00 M USD
0.00 USD
77.00 M USD
73.00 M USD
43.00 M USD
70.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
43.00 M USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Organon & Revenue by Segment (2/5)

  • 3 Years

  • Max

Nexplanon/Implanon NXT
Fosamax
Details
Date
Nexplanon/Implanon NXT
Fosamax
Jan 1, 2021
769.00 M USD
0.00 USD
Jan 1, 2022
834.00 M USD
152.00 M USD
Jan 1, 2023
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD

Organon & Revenue by Segment (3/5)

  • 3 Years

  • Max

Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Other Womens Health
Hadlima
Dulera
Fosamax
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Propecia
Ganirelix Acetate Injection
Proscar
Other Respiratory
Brenzys
Rosuzet
Aybintio
Details
Date
Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Other Womens Health
Hadlima
Dulera
Fosamax
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Propecia
Ganirelix Acetate Injection
Proscar
Other Respiratory
Brenzys
Rosuzet
Aybintio
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
175.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
457.00 M USD
411.00 M USD
357.00 M USD
326.00 M USD
323.00 M USD
273.00 M USD
226.00 M USD
238.00 M USD
241.00 M USD
229.00 M USD
204.00 M USD
19.00 M USD
180.00 M USD
0.00 USD
173.00 M USD
159.00 M USD
122.00 M USD
122.00 M USD
125.00 M USD
110.00 M USD
130.00 M USD
125.00 M USD
123.00 M USD
101.00 M USD
83.00 M USD
75.00 M USD
71.00 M USD
39.00 M USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Organon & Revenue by Segment (4/5)

  • Max

Nexplanon/Implanon NXT
Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Hadlima
Dulera
Fosamax
Other Women's Health
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Vtama
Propecia
Ganirelix Acetate Injection
Emgality/Rayvow
Proscar
Other Respiratory
Brenzys
Jada
Rosuzet
Aybintio
Details
Date
Nexplanon/Implanon NXT
Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Hadlima
Dulera
Fosamax
Other Women's Health
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Vtama
Propecia
Ganirelix Acetate Injection
Emgality/Rayvow
Proscar
Other Respiratory
Brenzys
Jada
Rosuzet
Aybintio
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
963.00 M USD
473.00 M USD
359.00 M USD
317.00 M USD
328.00 M USD
243.00 M USD
295.00 M USD
274.00 M USD
276.00 M USD
270.00 M USD
237.00 M USD
142.00 M USD
203.00 M USD
151.00 M USD
158.00 M USD
115.00 M USD
133.00 M USD
141.00 M USD
139.00 M USD
127.00 M USD
134.00 M USD
108.00 M USD
12.00 M USD
111.00 M USD
109.00 M USD
107.00 M USD
95.00 M USD
53.00 M USD
77.00 M USD
61.00 M USD
49.00 M USD
28.00 M USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Organon & Revenue by Segment (5/5)

  • Max

Nexplanon/Implanon NXT
Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Hadlima
Dulera
Fosamax
Other Women's Health
Emgality
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Vtama
Propecia
Ganirelix Acetate Injection
Proscar
Other Respiratory
Brenzys
Jada
Rosuzet
Other Biosimilars
Details
Date
Nexplanon/Implanon NXT
Atozet
Singulair
Zetia
Other
Cozaar/Hyzaar
Other Non-Opiod Pain, Bone and Dermatology
Renflexis
Nasonex
Arcoxia
Follistim AQ
Hadlima
Dulera
Fosamax
Other Women's Health
Emgality
NuvaRing
Other Cardiovascular
Ontruzant
Diprospan
Clarinex
Marvelon/Mercilon
Vytorin
Vtama
Propecia
Ganirelix Acetate Injection
Proscar
Other Respiratory
Brenzys
Jada
Rosuzet
Other Biosimilars
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
921.00 M USD
324.00 M USD
252.00 M USD
342.00 M USD
338.00 M USD
219.00 M USD
301.00 M USD
251.00 M USD
262.00 M USD
265.00 M USD
264.00 M USD
228.00 M USD
153.00 M USD
143.00 M USD
174.00 M USD
174.00 M USD
91.00 M USD
126.00 M USD
99.00 M USD
150.00 M USD
123.00 M USD
127.00 M USD
100.00 M USD
128.00 M USD
118.00 M USD
101.00 M USD
97.00 M USD
52.00 M USD
80.00 M USD
74.00 M USD
24.00 M USD
33.00 M USD

Organon & Revenue by Region

  • 3 Years

  • Max

International
Int’l
Europe and Canada
United States
Asia Pacific and Japan
Latin America, Middle East, Russia, and Africa
Latin America, Middle East, Russia and Africa
China
Other Countries
Details
Date
International
Int’l
Europe and Canada
United States
Asia Pacific and Japan
Latin America, Middle East, Russia, and Africa
Latin America, Middle East, Russia and Africa
China
Other Countries
Jan 1, 2021
4.92 B USD
0.00 USD
1.74 B USD
1.38 B USD
1.17 B USD
0.00 USD
841.00 M USD
933.00 M USD
233.00 M USD
Jan 1, 2022
4.74 B USD
0.00 USD
1.63 B USD
1.44 B USD
1.14 B USD
0.00 USD
895.00 M USD
917.00 M USD
151.00 M USD
Jan 1, 2023
0.00 USD
4.79 B USD
1.67 B USD
1.48 B USD
1.13 B USD
965.00 M USD
0.00 USD
864.00 M USD
154.00 M USD
Jan 1, 2024
0.00 USD
4.83 B USD
1.76 B USD
1.57 B USD
1.05 B USD
1.03 B USD
0.00 USD
847.00 M USD
137.00 M USD
Jan 1, 2025
0.00 USD
4.61 B USD
0.00 USD
1.60 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Organon & Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Organon & historical P/E ratio, EBIT multiple, and P/S ratio

Organon & annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Organon & shares outstanding

The number of shares of Organon & was 260.17 M in 2025. This indicates how many shares Organon & is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
254.55 M Stocks
Jan 1, 2022
255.39 M Stocks
Jan 1, 2023
256.59 M Stocks
Jan 1, 2024
259.88 M Stocks
Jan 1, 2025
260.17 M Stocks
Jan 1, 2026 (e)
260.17 M Stocks
Jan 1, 2027 (e)
260.17 M Stocks
Jan 1, 2028 (e)
260.17 M Stocks

Organon & Dividend History

6 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.02USDYTD—1×
Feb 23, 20260.02USD 0.0%1/1
20250.34USD↓ 69.6%4×
Feb 24, 20250.28USD 0.0%1/4
May 12, 20250.02USD↓ 92.9%2/4
Aug 15, 20250.02USD 0.0%3/4
Nov 20, 20250.02USD 0.0%4/4
20241.12USD 0.0%4×
20231.12USD 0.0%4×
20221.12USD↑ 100.0%4×
20210.56USD—2×

Organon & dividend history and estimates

In 2025, Organon & paid a dividend amounting to 0.34 USD. Dividend means that Organon & distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
0.56 USD
0.56 USD
Jan 1, 2022
1.12 USD
0.00 USD
Jan 1, 2023
1.12 USD
0.00 USD
Jan 1, 2024
1.12 USD
0.00 USD
Jan 1, 2025
0.34 USD
0.00 USD
Jan 1, 2026 (e)
0.02 USD
0.06 USD
Jan 1, 2027 (e)
0.00 USD
0.08 USD
Jan 1, 2028 (e)
0.00 USD
0.08 USD

Organon & dividend payout ratio

In 2025, Organon & had a payout ratio of 47.30%. The payout ratio indicates the percentage of the company's profits that Organon & distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
10.55 %
Jan 1, 2022
31.19 %
Jan 1, 2023
28.09 %
Jan 1, 2024
33.69 %
Jan 1, 2025
47.30 %
Jan 1, 2026 (e)
2.36 %
Jan 1, 2027 (e)
2.22 %
Jan 1, 2028 (e)
2.11 %

Current Organon & forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy6.25 % (1)
Hold37.50 % (6)
Sell56.25 % (9)
12M Price Target
9.18
Last Price
13.54
Currency
USD
12M Return Potential
-32.20 %
LTM Return
0 %

Organon & Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/11/20260.93USD1.58 BUSD2026 Q2
5/7/20260.84USD1.53 BUSD2026 Q1
4/30/20260.84USD1.51 BUSD2026 Q1
2/12/20260.74USD1.55 BUSD2025 Q4
2/11/20260.76USD1.56 BUSD2025 Q4
5/6/20241.17USD1.62 BUSD2024 Q1
2/5/20240.82USD1.57 BUSD2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Organon & stock

59/100
76
Environment
73
Social
30
Governance
E

Environment

20
Scope 1 - Direct Emissions30,360
Scope 2 - Indirect emissions from purchased energy24,479
Scope 3 - Indirect emissions within the value chain1,029,000
Total CO₂ emissions54,839
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees53
Percentage of women in management—
Percentage of Asian employees15
Share of Asian management17
Percentage of Hispanic/Latino employees8
Hispano/Latino Management share4
Percentage of Black employees7
Black Management Share9
Percentage of white employees68
White Management Share69
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Organon & shareholder structure

% Name
13.81934%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
10.87935%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.66205%
State Street Investment Management (US)
State Street Investment Management (US)
3.62778%
MFS Investment Management
MFS Investment Management
3.49660%
Millennium Management LLC
Millennium Management LLC
3.07311%
LSV Asset Management
LSV Asset Management
...

Organon & Executives and Management Board

KA

Mr. Kevin Ali

(64)

Chief Executive Officer, Director · since 2021

Compensation17.12 M USD
MW

Mr. Matthew Walsh

(58)

Chief Financial Officer, Executive Vice President

Compensation5.75 M USD
JM

Mr. Joseph Morrissey

(60)

Executive Vice President, Head of Manufacturing and Supply

Compensation4.13 M USD
JF

Dr. Juan Ferreira

(55)

Executive Vice President, Head of Research and Development and Chief Medical Officer

Compensation3.60 M USD
KW

Mr. Kirke Weaver

(52)

Executive Vice President, General Counsel, Corporate Secretary

Compensation3.19 M USD

Frequently asked questions about Organon &

Analysts currently set an average price target of 9.54 USD for the Organon & stock (median: 9.18 USD), implying -29.5 % versus the latest price. The consensus is based on 16 analyst ratings.

Organon & Analyst Price Targets 2026

All fundamentals and in-depth analysis of Organon &

Our stock analysis for Organon & stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Organon &. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Organon & Stock
Organon & Revenue→
Organon & Stock
Organon & Net Income→
Organon & Stock
Organon & P/E→
Organon & Stock
Organon & P/S→
Organon & Stock
Organon & EBIT→
Organon & Stock
Organon & Dividend→
Organon & Stock
Organon & Directors Dealings→
Organon & Stock
Organon & Stocks→
Organon & Stock
Organon & Market capitalization→
Organon & Stock
Organon & Debt→
Organon & Stock
Organon & Liabilities→
Organon & Stock
Organon & Equity→
Organon & Stock
Organon & AAQS→
Organon & Stock
Organon & Employees→
Organon & Stock
Organon & ROE→
Organon & Stock
Organon & ROA→
Organon & Stock
Organon & ROCE→
Organon & Stock
Organon & News→
Organon & Stock
Organon & Analyst Price Targets→

Health Stocks

OrgenesisOrganogenesis HoldingsOric PharmaceuticalsOrganiGram HoldingsOrient BioOrganigram GlobalOrient Europharma CoOrexoOrient Pharma CoOrchid PharmaOriola OyjOrchestra Biomed HoldingsAll Stocks A–Z →